ARASAFE - a randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m2 (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC
European Urology(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要